局部晚期直肠癌新辅助放化疗联合PD-1/PD-L1抑制剂的研究进展

doi:10.3760/cma.j.cn113030-20220614-00210

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Long-course concurrent chemoradiotherapy (CCRT) or short-course radiotherapy (SCRT) prior to surgery and postoperative chemotherapy is one of the main standard therapies for patients with locally advanced rectal cancer (LARC). On this basis, total neoadjuvant therapy (TNT) has been shown to improve disease-free survival, distant metastasis-free survival and complete response rates, whereas the 3-year distant recurrence rate is still above 20% and pathological complete response (pCR) is less than 30%. Long-term survival and adverse reactions remain to be improved. Currently, significant achivement has been obtained in immunotherapy. Application of immunotherapy in the treatment of rectal cancer remains to be urgently validated. In recent years, immunotherapy combined with preoperative chemoradiotherapy has been adopted for LARC in clinical trials. Besides, immunotherapy alone, especially programmed death-1 (PD-1) / programmed death ligand-1 (PD-L1) inhibitor, has also been utilized to treat colon rectal cancer. Relevant research progress was reviewed in this article.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Haoyue
	Jin Jing

Key words： Rectal neoplasms locally advanced Radio-immunotherapy Chemoradiotherapy Immune checkpoint inhibitor Research progress

Received: 14 June 2022

Corresponding Authors: Jin Jing,Email: jinjing@csco.org.cn

Cite this article:

Li Haoyue,Jin Jing. Immunotherapy in the neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Chinese Journal of Radiation Oncology, 2023, 32(8): 726-731.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20220614-00210 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2023/V32/I8/726

[1] Bujko K, Wyrwicz L, Rutkowski A, et al.Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study[J]. Ann Oncol, 2016,27(5):834-842. DOI: 10.1093/annonc/mdw062.
[2] Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021,22(1):29-42. DOI: 10.1016/S1470-2045(20)30555-6.
[3] Jin J, Tang Y, Hu C, et al.Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)[J]. J Clin Oncol, 2022,40(15):1681-1692. DOI: 10.1200/JCO.21.01667.
[4] Conroy T, Bosset JF, Etienne PL, et al.Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021,22(5):702-715. DOI: 10.1016/S1470-2045(21)00079-6.
[5] Zhu J, Liu AW, Sun XC, et al.Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer[J]. J Clin Oncol, 2020,38(36):4231-4239. DOI: 10.1200/JCO.20.01932.
[6] Deng YH, Chi P, Lan P, et al.Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial[J]. J Clin Oncol, 2019,37(34):3223-3233. DOI: 10.1200/JCO.18.02309.
[7] Kong JC, Soucisse M, Michael M, et al.Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and metaanalysis of oncological and operative outcomes[J]. Ann Surg Oncol, 2021,28(12):7476-7486. DOI: 10.1245/s10434-021-09837-8.
[8] Johnson D, Li L, Lee KC, et al.Total neoadjuvant therapy for high risk rectal cancer in Western and Asian populations - current evidence and clinical applications[J]. Clin Colorectal Cancer, 2022,21(1):45-54. DOI: 10.1016/j.clcc.2021.12.004.
[9] Aref A, Abdalla A.Total neoadjuvant therapy for locally advanced rectal cancer: induction or consolidation chemotherapy?[J]. J Clin Oncol, 2022,40(23):2515-2519. DOI: 10.1200/JCO.22.00506.
[10] Garcia-Aguilar J, Patil S, Gollub MJ, et al.Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy[J]. J Clin Oncol, 2022,40(23):2546-2556. DOI: 10.1200/JCO.22.00032.
[11] O'Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J]. PLoS One, 2017,12(12):e0189848. DOI: 10.1371/journal.pone.0189848.
[12] Le DT, Uram JN, Wang H, et al.PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015,372(26):2509-2520. DOI: 10.1056/NEJMoa1500596.
[13] Le DT, Diaz L, Kim TW, et al.432P Pembrolizumab (pembro) for previously treated, microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): final analysis of KEYNOTE-164[J]. Annals of Oncology, 2021, 32(S5):S550. DOI:10.1016/j.annonc.2021.08.953.
[14] Diaz LA, Shiu KK, Kim TW, et al.Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2022,23(5):659-670. DOI: 10.1016/S1470-2045(22)00197-8.
[15] Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncol, 2017,18(9):1182-1191. DOI: 10.1016/S1470-2045(17)30422-9.
[16] Overman MJ, Lonardi S, Wong K, et al.Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018,36(8):773-779. DOI: 10.1200/JCO.2017.76.9901.
[17] Lenz HJ, Van Cutsem E, Luisa Limon M, et al.First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study[J]. J Clin Oncol, 2022,40(2):161-170. DOI: 10.1200/JCO.21. 01015.
[18] Chalabi M, Fanchi LF, Dijkstra KK, et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nat Med, 2020,26(4):566-576. DOI: 10.1038/s41591-020-0805-8.
[19] Cremolini C, Rossini D, Antoniotti C, et al. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO[J]. Ann Oncol, 2021,32(S5):S1294-S1295. DOI:10.1016/j.annonc.2021.08.2094.
[20] Yang JB, Zhou W, Ma YF, et al.The response of PD-1 inhibitor combined with radiotherapy and GM-CSF(PRaG) with or without IL-2 in microsatellite stable metastatic colorectal cancer: analysis of pooled data from two phase II trials[J]. J Clin Oncol, 2022,40(suppl 16):e15561. DOI: 10.1200/JCO.2022.40.16_suppl.e15561.
[21] Chalabi M, Verschoor YL, van den Berg J, et al. LBA7 neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study[J]. Ann Oncol,2022,33(suppl 7):S1389. DOI: 10.1016/j.annonc.2022.08.016.
[22] Cercek A, Lumish M, Sinopoli J, et al.PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer[J]. N Engl J Med, 2022,386(25):2363-2376. DOI: 10.1056/NEJMoa2201445.
[23] Wang QX, Xiao BY, Cheng Y, et al.Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: a multicentre cohort study[J]. Eur J Cancer, 2022,174:176-184. DOI: 10.1016/j.ejca.2022.07.016.
[24] Deng LF, Liang H, Burnette B, et al.Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014,124(2):687-695. DOI: 10.1172/JCI67313.
[25] Grapin M, Richard C, Limagne E, et al.Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination[J]. J Immunother Cancer, 2019,7(1):160. DOI: 10.1186/s404 25-019-0634-9.
[26] Dewan MZ, Galloway AE, Kawashima N, et al.Fractionated but not single-dose radiotherapy induces an immune- mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clin Cancer Res, 2009,15(17):5379-5388. DOI: 10.1158/1078-0432.CCR-09-0265.
[27] Morisada M, Clavijo PE, Moore E, et al.PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation[J]. Oncoimmunology, 2018,7(3):e1395996. DOI: 10.1080/2162402X.2017.1395996.
[28] Dovedi SJ, Cheadle EJ, Popple AL, et al.Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade[J]. Clin Cancer Res, 2017,23(18):5514-5526. DOI: 10.1158/1078-0432.CCR-16-1673.
[29] Shamseddine A, Zeidan Y, Bouferraa Y, et al.SO-30 Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: averectal study[J]. Ann Oncol,2021,32(suppl 3):S215. DOI:10.1016/j.annonc.2021.05.054.
[30] Lin ZY, Cai M, Zhang P, et al.Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer[J]. J Immunother Cancer, 2021,9(11):e003554. DOI: 10.1136/jitc-2021-003554.
[31] Wang YQ, Xia F, Shen LJ, et al.Short-course radiotherapy combined with CAPOX and toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: preliminary findings from a randomized, prospective, multicenter, double-arm, phase II trial (TORCH)[J]. J Clin Oncol, 2022,40(Suppl 16): e15602. DOI: 10.1200/JCO.2022.40.16_suppl.e15602.
[32] Bando H, Tsukada Y, Inamori K, et al.Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer[J]. Clin Cancer Res, 2022,28(6):1136-1146. DOI: 10.1158/1078-0432.CCR-21-3213.
[33] George TJ, Yothers G, Jacobs SA, et al.Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2[J]. J Clin Oncol,2022,40(suppl 4):99. DOI:10.1200/JCO.2022.40.4_suppl.099.
[34] Tamberi S, Grassi E, Zingaretti C, et al. A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results[J]. J Clin Oncol,2022,40(suppl 17):LBA3513. DOI: 10.1200/JCO.2022.40.17_suppl.LBA3513.
[35] Salvatore L, Bensi M, Corallo S, et al.O-12 phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: the AVANA study[J]. Ann Oncol, 2021,32(suppl 3):S223. DOI: 10.1016/j.annonc.2021.05.016.
[36] Carrasco J, Schröder D, Sinapi I, et al.397P R-IMMUNE interim analysis: a phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer[J]. Ann Oncol,2021,32(suppl 5):S537. DOI:10.1016/j.annonc.2021.08.919.
[37] Johannes L, Irene K, Pils D, et al.Interim analysis of neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial[J]. J Clin Oncol,2022,40(suppl 16):e15604. DOI: 10.1200/JCO.2022.40.16_suppl.e15604.
[38] Rahma OE, Yothers G, Hong TS, et al.Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial[J]. JAMA Oncol, 2021,7(8):1225-1230. DOI: 10.1001/jamaoncol.2021.1683.
[39] Wu AW, Li YL, Ji DB, et al.PKUCH 04 trial: total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for pMMR/MSS locally advanced middle to low rectal cancer[J]. J Clin Oncol,2022,40(suppl 16):3609. DOI: 10.1200/JCO.2022.40.16_suppl.3609.
[40] Zhou LQ, Yu GY, Shen YX, et al.The clinical efficacy and safety of neoadjuvant chemoradiation therapy with immunotherapy for the organ preservation of ultra low rectal cancer: a single arm and open label exploratory study[J]. J Clin Oncol,2022,40(suppl 16):e15603. DOI: 10.1200/JCO.2022.40.16_suppl.e15603.